NeuroSurvival Technologies Ltd. has raised $13.3 million in a new round of financing and has changed its name to Aposense, the same name as its molecular imaging agent for programmed cell death. The company plans to use the funds to finance late-stage trials of the imaging agent, NST CEO Yoram Ashery said.

Related Summaries